|
|
|
|
| LEADER |
01466naa a2200349 i 4500 |
| 001 |
NSK01001091125 |
| 003 |
HR-ZaNSK |
| 005 |
20210219091200.0 |
| 007 |
ta |
| 008 |
210219s2018 ci a | |0|| ||eng |
| 035 |
|
|
|a (HR-ZaNSK)001091125
|
| 040 |
|
|
|a HR-ZaNSK
|b hrv
|c HR-ZaNSK
|e ppiak
|
| 042 |
|
|
|a croatica
|
| 044 |
|
|
|a ci
|c hr
|
| 080 |
1 |
|
|a 616
|2 2011
|
| 080 |
1 |
|
|a 615
|2 2011
|
| 100 |
1 |
|
|a Glamočlija, Una
|4 aut
|
| 245 |
1 |
0 |
|a Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro :
|b a retrospective pharmacoepidemiological study /
|c Una Glamočlija, Biljana Tubić, Martin Kondža, Aleksandar Zolak, Nataša Grubiša.
|
| 300 |
|
|
|b Ilustr.
|
| 500 |
|
|
|a Tematski blok: Gastroesophageal refux disease, Barrett esophagus, and esophagel adenocarcinoma - where do we stand?
|
| 504 |
|
|
|a Bibliografija: 25 jed.
|
| 653 |
|
0 |
|a Farmakovigilancija
|a Lijekovi
|a Nuspojave
|a Farmakoepidemiologija
|
| 653 |
|
5 |
|a Bosna i Hercegovina
|a Hrvatska
|a Srbija
|a Crna Gora
|
| 653 |
|
6 |
|a Studija
|
| 700 |
1 |
|
|a Tubić, Biljana
|4 aut
|9 HR-ZaNSK
|
| 700 |
1 |
|
|a Kondža, Martin
|4 aut
|9 HR-ZaNSK
|
| 700 |
1 |
|
|a Zolak, Aleksandar
|4 aut
|9 HR-ZaNSK
|
| 700 |
1 |
|
|a Grubiša, Nataša
|4 aut
|9 HR-ZaNSK
|
| 773 |
0 |
|
|t Croatian medical journal
|x 0353-9504
|g 59 (2018), 3 ; str. 124-131
|w nsk.(HR-ZaNSK)000006721
|
| 981 |
|
|
|b B08/18
|
| 998 |
|
|
|b gtao2102
|
| 856 |
4 |
1 |
|u https://hrcak.srce.hr/237475
|y Elektronička verzija članka
|